It refers to the use of the Cannabis sativa plant or its derivatives for therapeutic purposes, under medical prescription and supervision.
📚 WHO – Cannabis: Health and Human Rights, 2019
The plant contains various compounds, primarily cannabinoids—especially THC (tetrahydrocannabinol), which is psychoactive, and CBD (cannabidiol), which is non-psychoactive.
📚 WHO – Cannabidiol (CBD) Critical Review Report, 2018
The WHO recognizes scientific evidence for use in:
– Refractory epilepsy
– Chronic pain
– Spasticity related to multiple sclerosis
– Chemotherapy-induced nausea and vomiting
📚 WHO – The Health and Social Effects of Nonmedical Cannabis Use, 2016
Only in specific cases, with clinical support and scientific evidence. It should not be used as a blanket replacement for conventional therapies.
📚 WHO – Expert Committee on Drug Dependence, 2018
Yes. ANVISA authorizes medical use with a prescription. Personal importation is regulated by RDC No. 660/2022, and domestic sales follow RDC No. 327/2019, which sets rules for manufacturing, prescription, and sales in pharmacies.
📚 ANVISA – RDC 660/2022 and RDC 327/2019
They include sublingual oil, capsules, oral sprays, vaporized inhalation, and medications containing purified THC or CBD.
📚 WHO – Cannabis: Health and Human Rights, 2019
CBD does not have addiction potential. THC can lead to dependence, especially with prolonged and unsupervised use.
📚 WHO – The Health and Social Effects of Nonmedical Cannabis Use, 2016
Only physicians legally authorized to practice, in accordance with the health regulations of each country.
📚 WHO – Cannabis: Health and Human Rights, 2019